Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Stocks to Buy for the Long Term. Eli Lilly (LLY) Taps Gene-Editing Technology to Target Hearing Loss, Reuters Reports According to a report by Reuters, Eli Lilly and Company (NYSE:LLY) has signed an agreement worth up to $1.12 billion with Seamless Therapeutics. The Germany-based startup announced the deal on January 28. The partnership focuses on developing and commercializing treatments for hearing loss using Seamless’ gene-editing platform ...

核心观点 - 美国医疗保险即将覆盖肥胖症治疗 可能极大扩展礼来公司实验性减肥口服药orforglipron的可及性 公司首席执行官对此表示看好 [1] - 礼来公司正为口服药全面上市做准备 预计其将与医保覆盖生效时间相配合 尽管初期定价协议可能带来成本下降 但公司预计2026年下半年患者覆盖扩大后将推动销量加速增长 [3] - 诺和诺德在GLP-1药物广告支出上大幅超过礼来 显示出肥胖和糖尿病市场竞争加剧 [5] 市场与患者覆盖 - 医疗保险覆盖有望解锁2000万至3000万潜在符合条件的患者 使GLP-1疗法变得更加可负担且使用更广泛 [2] - 公司对口服药满足注射疗法之外“更多患者”的需求充满信心 认为其市场潜力强劲 [4] 产品上市与竞争动态 - 礼来公司计划在第二季度推出orforglipron 与今年晚些时候生效的医疗保险覆盖时间相吻合 [3] - 诺和诺德在2025年1月至9月期间 为其GLP-1明星产品Wegovy和Ozempic的美国广告支出估计分别为3.16亿美元和1.69亿美元 较2024年同期分别增长54%和44% [5] - 相比之下 礼来同期为其减肥药Zepbound的广告支出约为1.31亿美元（上年为200万美元） 为其糖尿病治疗药物Mounjaro的广告支出为8300万美元 [6] 公司财务与股价 - 诺和诺德与礼来公司均计划于2月4日周三市场开盘前公布第四季度财报 [6] - 礼来公司股价周五收盘报1037.15美元 上涨1.27% 盘后交易中微跌0.12%至1035.88美元 [6]

Everyone loves a good comeback story, and that's especially true in markets where business cycles ebb and flow. Last year's winners frequently turn into this year's laggards, and we've already seen examples of that this month as software stocks plunge and memory stocks soar.Today, we'll look at five stocks with comeback potential in 2026. The theme connecting these five companies is their miserable performance in 2025, and the steps they've taken to prove investors wrong in 2026.Each stock is off to a hot s ...

公司资本支出与产能扩张 - 礼来公司宣布将投资35亿美元在宾夕法尼亚州福格斯维尔建设新的生产设施 [1] - 新设施将生产注射类药物和器械，包括仍在研究阶段、尚未公开使用的每周一次注射减肥药retatrutide [3] - 该设施的建设预计于今年开始，2031年完工 [3] - 此次投资是公司更广泛的国内扩张计划的一部分，该计划还包括此前宣布的在德克萨斯州、弗吉尼亚州和阿拉巴马州的新工厂，以及印第安纳州正在建设中的另一处设施 [2] 公司财务与产品表现 - 公司第三季度利润达到创纪录的55.8亿美元 [4] - 公司第三季度营收为176亿美元，较上年同期增长超过50% [4] - 仅减肥药Zepbound和糖尿病药Mounjaro两款产品在第三季度的销售额就达到100亿美元 [4] 行业与市场背景 - 公司的扩张旨在利用肥胖症和糖尿病治疗药物销售激增的市场机会 [1] - 礼来公司是减肥治疗药物Zepbound和糖尿病药物Mounjaro的生产商 [2]

公司整体业绩预期 - 华尔街分析师预计礼来公司即将公布的季度每股收益为6.99美元，同比增长31.4% [1] - 预计季度营收将达到178.7亿美元，同比增长32.1% [1] - 过去30天内，季度每股收益的共识预期被下调了8.6% [2] 关键产品销售预期 - 明星糖尿病药物Mounjaro在美国市场的净销售额预计为37.7亿美元，同比增长43.1%，是增长的主要驱动力 [6] - 抗癌药物Cyramza的净销售额预计为2.5617亿美元，同比微降0.9% [5] - 胰岛素产品Humalog和Humulin预计销售额分别为5.7003亿美元和2.0425亿美元，同比分别下降8.1%和27.1% [5] - 骨质疏松药物Forteo预计销售额为5529万美元，同比下降10.3% [6] 分区域业绩预期 - 美国市场总营收预计为119.9亿美元，同比增长32.8% [7] - 美国以外市场对非关联客户的营收预计为60.4亿美元，同比增长34.1% [6] - 美国市场部分产品表现疲软：Alimta预计销售额862万美元（-31.1%），Forteo预计2394万美元（-12%），Humalog预计3.5337亿美元（-12.9%），Humulin预计1.2799亿美元（-25.2%）[7][8] - 国际市场Alimta预计销售额为1948万美元，同比下降26.2% [8] 市场表现与共识 - 过去一个月，公司股价回报率为-4.7%，同期标普500指数上涨0.9% [9] - 盈利预测的修正趋势是预测股票短期价格表现的重要因素 [3] - 分析关键业务指标的预测有助于获得对公司业绩更深入的洞察 [4]

礼来公司市场地位与表现 - 礼来公司是全球市值最高的医疗保健公司，市值约为9500亿美元 [1] - 过去五年，公司股价飙升了400%，主要得益于其GLP-1药物Mounjaro和Zepbound的受欢迎程度激增 [1] - Mounjaro已获批用于糖尿病治疗，Zepbound已获批用于减肥 [1] GLP-1药物市场前景与竞争格局 - GLP-1药物市场在未来十年内价值可能超过1500亿美元 [6] - 市场有足够的空间容纳礼来及其他公司获取可观的市场份额 [6] - 安进公司正在开发一种有前景的GLP-1药物MariTide，这是一种每月仅需注射一次的治疗方案 [3] - 相比之下，礼来的Mounjaro和Zepbound均为每周注射剂 [3] - 安进首席执行官表示，数据显示MariTide的使用频率可能更低，或许每季度一次 [3] 安进公司药物MariTide的潜力 - 在临床试验中，MariTide在52周内可帮助患者减轻高达20%的体重，效果与目前已获批的GLP-1疗法相当 [4] - 尽管许多人可能更倾向于口服药片，但如果使用MariTide意味着每年仅需治疗四次，这可能会成为市场上大部分患者的首选方案 [4] - MariTide目前处于3期试验阶段，若最终获得批准，可能为安进股价带来巨大的上涨空间 [5] 安进公司估值与投资吸引力 - 过去五年，安进股价涨幅相对温和，为34% [5] - 根据分析师预期，安进股票的远期市盈率为16倍 [5] - 相比之下，投资者为礼来股票支付的远期市盈率为32倍 [5] - 与礼来相比，安进估值较低，且存在可能推动其股价大幅上涨的催化剂，使其成为当前颇具吸引力的医疗保健股 [6]

Key Takeaways Roche reported robust, placebo-adjusted weight loss up to 22.5% at 48 weeks with once-weekly CT-388.RHHBY said 47.8% on the top dose lost at least 20% body weight, while 26.1% lost over 30% by week 48.Roche said CT-388 was well tolerated, with low discontinuation rates and expected mild GI side effects.Roche Holding AG (RHHBY) announced positive top-line data from a mid-stage study of its investigational candidate, CT-388, being developed for the treatment of obesity. CT-388 is a once-weekly i ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the fourth quarter of 2025. A copy of the letter can be downloaded here. Global equity markets delivered robust results in the quarter, backed by easing inflation trends and strong economic data. The Hardman Johnston Global Equity Strategy returned 2.91%, net of fees, compared to the MSCI AC World Net Index’s 3.29% gain. The Financials and Consumer Staples sectors c ...

By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its ​rival medicines, as the Danish drugmaker fought for market share, data seen by Reuters shows. The data from advertising tracking firm MediaRadar, ‌which has not been previously reported, shows Novo spent an estimated $316 million advertising its weight-los ...

Key Points Novo Nordisk stock lost 40% of its value in 2025. The stock is already trading up 22% in 2026. 10 stocks we like better than Novo Nordisk › 2025 was a miserable year to own Novo Nordisk (NYSE: NVO) stock. Shares of the Danish pharmaceuticals giant and inventor of Wegovy and Ozempic crashed 40% last year as the company steadily lost market share to rivals such as Eli Lilly (NYSE: LLY), which has competing Mounjaro and Zepbound drugs, and Novo Nordisk's earnings fell in tandem. Novo Nordi ...